View Older Stories View More Recent Stories

Jan 3, 2024 07:00AM Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 5, 2023 06:00AM Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
Nov 8, 2023 07:00AM Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
Nov 1, 2023 07:00AM Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
Oct 27, 2023 07:00AM Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
Oct 3, 2023 07:00AM Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
Oct 2, 2023 08:20AM Amicus Therapeutics (FOLD) and Blackstone (BX) Enter into $430 Million Strategic Financing Collaboration
Oct 2, 2023 08:20AM Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Sep 28, 2023 10:41AM Amicus Therapeutics (FOLD) Announces FDA Approval and Launch of Pombiliti + Opfolda
Sep 28, 2023 10:41AM Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Sep 1, 2023 07:00AM Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
Aug 29, 2023 07:00AM Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
Aug 21, 2023 07:00AM Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Aug 15, 2023 07:00AM Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Aug 8, 2023 07:00AM Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
Jul 31, 2023 07:00AM Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
Jun 27, 2023 07:00AM Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
May 10, 2023 07:00AM Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 2, 2023 07:00AM Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 1, 2023 07:00AM Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
Apr 26, 2023 01:01PM Amicus Therapeutics (FOLD) Receives Positive CHMP Opinion for Opfolda
Apr 26, 2023 01:00PM Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
Mar 27, 2023 07:03AM Amicus Therapeutics (FOLD) Announces European Commission Approval for Pombiliti
Mar 27, 2023 07:00AM Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Mar 1, 2023 07:00AM Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
Feb 27, 2023 07:00AM Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Feb 22, 2023 05:00PM Amicus Therapeutics (FOLD) Reports Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA
Feb 22, 2023 05:00PM Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Feb 14, 2023 07:00AM Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
Feb 13, 2023 07:00AM Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
Feb 8, 2023 07:00AM Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
Jan 9, 2023 07:17AM Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus
Jan 9, 2023 07:00AM Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
Jan 3, 2023 07:00AM Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 16, 2022 08:11AM Amicus Therapeutics (FOLD) Receives Positive CHMP Opinion for Pombiliti for Late-Onset Pompe Disease
Dec 16, 2022 08:10AM Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
Nov 15, 2022 07:00AM Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
Nov 7, 2022 07:00AM Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
Oct 28, 2022 04:01PM Amicus Therapeutics (FOLD) Announces FDA Deferral of Action on Filing for AT-GAA in Late-onset Pompe Disease
Oct 28, 2022 04:01PM U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
Oct 27, 2022 07:00AM Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
Oct 11, 2022 07:00AM Amicus Therapeutics Announces Participation at World Muscle Society 2022
Sep 21, 2022 07:00AM Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
Sep 8, 2022 07:00AM Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 4, 2022 07:00AM Amicus Therapeutics Announces Second Quarter 2022 Financial Results
Jul 26, 2022 07:00AM Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
Jun 8, 2022 07:00AM Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 10, 2022 04:01PM Amicus Therapeutics (FOLD) Announces 90-Days PDUFA Date Extensions for AT-GAA
May 10, 2022 04:01PM Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
May 9, 2022 09:15AM CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
View More Recent Stories View Older Stories